New Risk-Adapted drug combo aims to outsmart lymphoma

NCT ID NCT06793189

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a personalized approach to treating marginal zone lymphoma, a slow-growing blood cancer. Researchers assign patients to different drug combinations based on their risk score, using targeted therapies like obinutuzumab, orelabrutinib, and lenalidomide. The goal is to improve how long the cancer stays away while keeping side effects manageable. About 145 newly diagnosed patients who need systemic treatment will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obinutuzumab, orelabrutinib, and lenalidomide
What this could lead to: If successful, this could provide a more personalized, effective treatment for marginal zone lymphoma, potentially improving long-term disease control and reducing side effects.
What could go wrong: This is a Phase 2 trial with only 145 participants, so results may not apply to everyone. The drugs can cause serious side effects like infections, low blood counts, and organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL)

Contacts and locations

Locations

Affiliated First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, China
Peking University Third Hospital
RECRUITING

Beijing, China
Shanghai Ruijin Hospital
RECRUITING

Shanghai, China, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.